3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
26
Leukemia, Myeloid, Acute
24
Lymphoma, Non-Hodgkin
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Leukemia
19
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Hodgkin Disease
16
Hematologic Neoplasms
16
Lymphoma
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Multiple Myeloma
11
Myeloproliferative Disorders
10
Graft vs Host Disease
9
Primary Myelofibrosis
8
Leukemia, Myelomonocytic, Juvenile
8
Lymphoma, Mantle-Cell
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma, Follicular
7
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Myelomonocytic, Chronic
6
Neoplasms
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Myeloid, Accelerated Phase
5
Burkitt Lymphoma
5
Anemia, Refractory, with Excess of Blasts
5
Leukemia, Myeloid, Chronic-Phase
4
Congenital Abnormalities
4
Blast Crisis
4
Waldenstrom Macroglobulinemia
3
Neuroblastoma
3
Interventions
Cyclophosphamide
10
ofatumumab
8
fludarabine
6
Rituximab
5
fludarabine phosphate
4
Bendamustine Hydrochloride
4
venetoclax
3
obinutuzumab
3
ibrutinib
3
acalabrutinib
3
Melphalan
3
pirtobrutinib
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Lenalidomide
2
Immunotherapy, Adoptive
2
Busulfan
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
pomalidomide
1
pivalyloxymethyl butyrate
1
pegaspargase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, B-Cell
×
thymoglobulin
×
Clear all
NCT03852407
2022-10-12
HLA
University of Liege
Phase 2
Recruiting
114 enrolled